
ASTH Stock Forecast & Price Target
ASTH Analyst Ratings
Bulls say
Astrana Health is expected to continue its positive trajectory with the end of the ACO REACH program and the adoption of the new LEAD model, as demonstrated by the 8.4% savings and 75% quality score of its ACOs in the program. Moreover, Astrana's payer-agnostic platform and partnerships with a wide range of health plans, along with its focus on preventive care for seniors, position it well in the industry alongside other successful companies such as Privia, Oak Street, and Agilon Health. With a strong balance sheet and a proven track record in the value-based care space, Astrana Health's stock is expected to continue its upward trend, making it a promising investment opportunity.
Bears say
Astrana Health is well-positioned for long-term growth and success in the value-based care space, with its strong track record in delivering high-quality care and generating cost-savings. Its ACO REACH programs are performing well, with a savings rate above the industry average. The acquisition of Prospect Medical and its Knox Keene License positions Astrana to capture more capitated premiums in the future. However, the company's heavy reliance on Medicare and Medicaid revenue and potential risks from changes in healthcare legislation and increased competition in the market should be closely monitored. The stock is currently undervalued compared to its peers, and its strong cash flow generation in Q1 and Q2 is expected to support its growth.
This aggregate rating is based on analysts' research of Astrana Health Inc and is not a guaranteed prediction by Public.com or investment advice.
ASTH Analyst Forecast & Price Prediction
Start investing in ASTH
Order type
Buy in
Order amount
Est. shares
0 shares